Victory Capital Management
ATYR

Victory Capital Management’s aTyr Pharma ATYR Stock Holding History

Victory Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-88,436
Closed -$69K – 2573
2026
Q1 		$69K Sell
88,436
-93,530
-51% -$79K ﹤0.01% 2295
2025
Q4 		$142K Sell
181,966
-10,847
-6% -$8.9K ﹤0.01% 2241
2025
Q3 		$139K Buy
192,813
+182,551
+1,779% +$827K ﹤0.01% 2261
2025
Q2 		$52K Buy
+10,262
New +$40.4K ﹤0.01% 2378
2025
Q1 		– Sell
-10,138
Closed -$36.7K – 2520
2024
Q4 		$36.7K Buy
+10,138
New +$30.7K ﹤0.01% 2416
2020
Q2 		– Sell
-1,301
Closed -$4K – 3328
2020
Q1 		$4K Buy
+1,301
New +$5.62K ﹤0.01% 3372
2019
Q4 		– Sell
-443
Closed -$2K – 3318
2019
Q3 		$2K Buy
+443
New +$1.63K ﹤0.01% 3652
2017
Q4 		– Sell
-6,430
Closed -$455K – 1842
2017
Q3 		$455K Buy
+6,430
New +$298K ﹤0.01% 1338

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management's ATYR Position: Q2 2026 in Review

Victory Capital Management sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 88,436 shares — an estimated $69K sold.

Victory Capital Management first reported a position in ATYR in Q3 2017 and held it in 8 quarters. The position peaked at $455K in Q3 2017. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Victory Capital Management reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
  • Victory Capital Management sold 88,436 aTyr Pharma shares in Q2 2026, an estimated $69K.
  • Victory Capital Management first reported a position in aTyr Pharma in Q3 2017 and held it in 8 quarters.
  • Victory Capital Management's aTyr Pharma position peaked at $455K in Q3 2017.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.